Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies
Y Zhao, C **ng, Y Deng, C Ye, H Peng - Genes & Diseases, 2024 - Elsevier
The hypoxic microenvironment is an essential characteristic of most malignant tumors.
Notably, hypoxia-inducible factor-1 alpha (HIF-1α) is a key regulatory factor of cellular …
Notably, hypoxia-inducible factor-1 alpha (HIF-1α) is a key regulatory factor of cellular …
Relapsed/refractory diffuse large B-cell lymphoma
JW Friedberg - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Despite overall improvements in outcomes of diffuse large B-cell lymphoma (DLBCL),
approximately one-third of patients will develop relapsed/refractory disease that remains a …
approximately one-third of patients will develop relapsed/refractory disease that remains a …
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a …
B Coiffier, C Thieblemont… - Blood, The Journal …, 2010 - ashpublications.org
We report the outcome of patients included in the LNH-98.5 study, which compared
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus …
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus …
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy
Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the …
a time-to-event approach with relapse, re-treatment, and death commonly used as the …
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
Recent studies have shown limited utility of routine surveillance imaging for diffuse large B-
cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by …
cell lymphoma (DLBCL) patients achieving remission. Detection of molecular disease by …
Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus–related lymphoproliferative disorder after hematopoietic stem cell transplant in …
J Styczynski, L Gil, G Tridello… - Clinical infectious …, 2013 - academic.oup.com
Background. The objective of this analysis was to investigate prognostic factors that
influence the outcome of Epstein-Barr virus (EBV)–related posttransplant lymphoproliferative …
influence the outcome of Epstein-Barr virus (EBV)–related posttransplant lymphoproliferative …
Management of relapsed/refractory DLBCL
C Sarkozy, LH Sehn - Best Practice & Research Clinical Haematology, 2018 - Elsevier
Diffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma.
Although the curability rate is high, around 40% of patients will relapse or exhibit refractory …
Although the curability rate is high, around 40% of patients will relapse or exhibit refractory …
[PDF][PDF] Guidelines for the management of diffuse large B-cell lymphoma
1Department of Haematology, Queen Elizabeth Hospital, Birmingham, 2Department of
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an …
Purpose Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral
testis, CNS, and extranodal sites. To prevent these events, we designed an international …
testis, CNS, and extranodal sites. To prevent these events, we designed an international …
Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group …
DM Stephens, H Li, ML LeBlanc… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Utility of combined-modality therapy for patients with limited-stage diffuse large B-
cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 …
cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 …